IBC Meetings and Proposal Submission Deadlines
IBC Meetings are held at noon to 2 p.m. on the fourth Thursday of every month in room 113, Riverbend South (Old CCRC) unless noted otherwise. Protocols must be submitted for full IBC review no later than one month prior to the scheduled meeting date. Protocols received after that date will be put on the agenda for the following month’s meeting.
IBC Meeting Schedule
|Submission Date for Full Committee Review||Meeting Date|
|No meeting in November|
|Name of IBC Member or Code||Degree/Credentials||Position Title||NIH Policy Membership Requirements|
|Eric Lafontaine||PhD||Professor – Infectious Disease||IBC Chair|
|1||M.Ed, Ed.D||Retired - Senior Public Service Associate||Nonaffiliated, Community Member|
|2||PhD||Professor - Horticulture||Scientist|
|3||MS||Research Professional||Lab tech staff|
|4||MD, MPH||Director - Occ Health Services||Occ Health Physician|
|5||PhD||Associate Professor - Infectious Disease||Scientist|
|6||PhD||Professor – Microbiology||Scientist|
|7||MBA||Director - Engineering||Ex-Officio - nonscientist|
|8||DVM||Director – URAR||Veterinarian|
|9 Patrick Stockton||MS, RBP||Director of Biosafety||Biosafety Officer/RO|
|10||PhD||Professor – Cellular Biology||Scientist|
|11||PhD|| Associate Professor – Pharmaceutical and Biomedical Sciences||Scientist|
|12||MS||Director - Research Safety and Support||Nonscientist|
|13||PhD||Retired - USDA||Nonaffiliated, Community Member|
|14||DVM, DACLAM||Director of Research Compliance||Alternate for 8|
|15 Manley Kiser||MS||Associate Biosafety Officer||Alternate for 9|
|16||PhD||Associate Professor - Infectious Disease||Alternate for 5|
|17 Nancy Mead||SM(NRCM)||Biosafety Manager||IBC Coordinator|
|18||BS||Research Professional||Alternate for 3|
NIH Guidelines for Research Involving Recombinant DNA Training
Irrespective of funding resources, all research or teaching projects at the University of Georgia that involve the use of recombinant DNA techniques must be reported to the Institutional Biosafety Committee (IBC) for review and approval. In order to full-fill this federally mandated requirement, researchers must understand which classification of recombinant DNA use covers their work according to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules (NIH Guidelines).
While conducting research subject to the NIH Guidelines, the PI must:
- Determine the need for IBC review before modifying recombinant or synthetic nucleic acid research already approved by the IBC.
- Submit any subsequent changes (e.g., changes in the source of DNA or host-vector system) to the IBC for review and approval or disapproval.
- Remain in communication with the IBC throughout the duration of the project.
- Report any significant problems pertaining to the operation and implementation of containment practices and procedures, violations of the NIH Guidelines, or any significant research-related accidents and illnesses to the IBC, NIH OBA, and, as applicable, the Biological Safety Officer, Greenhouse or Animal Facility Director, and other appropriate authorities.
To assist researchers with the understanding of these guidelines and to establish effective reporting to the IBC, the Office of Biosafety has provided the following overview documents for training purposes. These overview documents, provided by the NIH, some of which have been modified by the UGA Biosafety Officer, will aid in better understanding the responsibilities and scope associated with the NIH Guidelines.